# Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC

> **NCT03543683** · PHASE2 · COMPLETED · sponsor: **Daping Hospital and the Research Institute of Surgery of the Third Military Medical University** · enrollment: 115 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer Stage IIIB
- Non-small Cell Lung Cancer Stage IV
- EGFR T790M

## Interventions

- **DRUG:** Osimertinib
- **DRUG:** Aspirin

## Key facts

- **NCT ID:** NCT03543683
- **Lead sponsor:** Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-01
- **Primary completion:** 2023-01-31
- **Final completion:** 2024-06-01
- **Target enrollment:** 115 (ACTUAL)
- **Last updated:** 2025-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03543683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03543683, "Combination of Osimertinib and Aspirin to Treat 1st Generation EGFR-TKI Resistance in NSCLC". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT03543683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*